⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 13, 2013New England Journal of MedicineOpen Access

BRAF V600E Inhibition in Anaplastic Thyroid Cancer

View Full Paper

Ask AI

Bookmark

Share

Abstract

A patient with rapidly progressive anaplastic thyroid cancer bearing the BRAF V600E mutation has a dramatic response to vemurafenib.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rosove et al. (2013) studied this question.

synapsesocial.com/papers/6a8654ab16da06070a73a06f https://doi.org/10.1056/nejmc1215697

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Late Intervention with anti-BRAFV600E Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid CancerOriginal Research · 2011 · 60 citations
2BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary CarcinomasOriginal Research · 2003 · 1,046 citations
3Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationHuman Clinical Trial · 2011 · 7,741 citations
4BRAF Inhibition in Refractory Hairy-Cell LeukemiaOriginal Research · 2012 · 256 citations
5BRAFV600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomasOriginal Research · 2007 · 59 citations